Levetiracetam Solution
Product Images NDC 70752-203

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 70752-203). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Quagen Pharmaceuticals Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemstructure (Chemstructure)

Chemical structure diagram of the active ingredient levetiracetam, showing its molecular layout with a pyrrolidone ring and attached functional groups.*

FDA Label Image

Conatinerlabel473 (Conatinerlabel473)

Label for Levetiracetam Oral Solution USP 100 mg/mL by Quagen Pharmaceuticals LLC. The label shows a 16 fl oz (473 mL) bottle intended for oral use, with dosing and storage instructions. It notes pharmacist dispensing guidance and includes a barcode and manufacturing details from West Caldwell, NJ.*

FDA Label Image

Image Description (Fig1)

A text panel displaying a formula to calculate the total daily dose in mL/day of a medication. The formula divides the product of daily dose in mg/kg/day and patient weight in kg by the concentration of 100 mg/mL.*

FDA Label Image

Fig2 (Fig2)

A text panel showing a mathematical formula for calculating creatinine clearance (CLcr) based on age, weight, and serum creatinine, with an adjustment factor of 0.85 for female patients.*

FDA Label Image

Fig3 (Fig3)

A formula expressing creatinine clearance normalized to body surface area, showing clearance (mL/min) divided by body surface area (m2) multiplied by 1.73 m2. This pharmacokinetic calculation is presented as a text panel.*

FDA Label Image

Fig4 (Fig4)

A bar graph titled 'Responder Rate (≥ 50% Reduction From Baseline) In Study 1' showing the percentage of patients responding to placebo, 1000 mg/day Levetiracetam, and 3000 mg/day Levetiracetam. The graph displays approximately 7.4% response for placebo (N=95), 37.1% for Levetiracetam 1000 mg/day (N=97), and 39.6% for Levetiracetam 3000 mg/day (N=101), with asterisks indicating statistically significant differences versus placebo.*

FDA Label Image

Fig5 (Fig5)

A bar chart showing responder rates (≥ 50% reduction from baseline) in Study 2, Period A. It compares placebo with Levetiracetam at 1000 mg/day and 2000 mg/day doses. The % of patients responding increases from 6.3% (placebo) to 20.8% and 35.2% for the respective Levetiracetam doses, with statistical significance noted.*

FDA Label Image

Fig6 (Fig6)

A bar graph comparing responder rates (>50% reduction from baseline) in Study 3 for placebo versus Levetiracetam 3000 mg/day. The graph shows 14.4% responder rate for placebo (N=104) and 39.4% for Levetiracetam (N=180), with a notation indicating statistical significance for Levetiracetam versus placebo. The y-axis represents percentage of patients from 0% to 45%.*

FDA Label Image

Fig7 (Fig7)

A bar graph depicting the responder rate (≥ 50% reduction from baseline) in a clinical study comparing placebo and levetiracetam. The vertical axis shows the percentage of patients, with placebo at 19.6% and levetiracetam at 44.6%, highlighting a statistically significant higher responder rate for levetiracetam versus placebo.*

FDA Label Image

Fig8 (Fig8)

A bar graph depicting the responder rate for patients ages 1 month to under 4 years in Study 5, comparing placebo and Levetiracetam groups. The y-axis shows the percentage of patients, with placebo at 19.6% and Levetiracetam at 43.1%, indicating a statistically significant higher response for Levetiracetam versus placebo.*

FDA Label Image

Fig9 (Fig9)

A bar graph titled 'Responder Rate (≥ 50% Reduction From Baseline) In PGTC Seizure Frequency Per Week In Study 7' showing the percentage of patients who responded to treatment. The x-axis compares Placebo (N=84) and Levetiracetam (N=79). The y-axis shows percentage of patients from 0% to 100%. The Placebo group has a responder rate of 45.2%, while the Levetiracetam group shows a higher responder rate of 72.2%, marked as statistically significant versus placebo.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.